We have revised up our FY21E EBITDA by 7% on lower-than-estimated cost in 2QFY21. Our FY22E revenue/EBITDA estimates are largely maintained; we factor in 11%/14% growth over FY20. Revival in earnings and a low valuation make it attractive. Maintain Buy....